Belite Bio, Inc.

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration. Its lead product candidate, Tinlarebant (LBS-008), is an orally administered therapy in phase 3 clinical trials, such as the DRAGON, DRAGON II, and PHOENIX studies, targeting adolescent and adult patients to slow retinal lesion growth by inhibiting retinol-binding protein 4. The company has received regulatory designations including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug, with applications accepted by agencies like China's NMPA and the UK's MHRA. Additionally, Belite Bio advances LBS-009, an oral anti-retinol-binding protein 4 therapy in preclinical development for liver diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Founded in 2016 and headquartered in San Diego, California, Belite Bio plays a key role in addressing vision loss through innovative small-molecule treatments.